Inhaled antibodies: Quality and performance considerations

References

• Fellner R, Terryah S, Tarran R. Inhaled protein/peptide-based therapies for repsiratory disease. Mol Cell Peiatr. 2016;3:1.
   PubMedGoogle Scholar
• Matthews A, Ee P, Ge R. Developing inhaled protein therapeutics for lung diseases. Molecular Biomedicine. 2020;1:11.
   Google Scholar
• Barnett A. Exubera inhaled insulin: a review. Int J Clinical Practice. 2004;58:394–10.
   PubMed Web of Science ®Google Scholar
• Pressler T. Review of recombinant human deoxyribonuclease (rhDNas) in management of patients with cycstic fibrosis. Biologics. 2008;2:611–17.
   PubMedGoogle Scholar
• Adjei A, Gupta P. Inhalation delivery of therapeutic peptides and proteins. New York (NY): Marcel Dekker; 1997.
   Google Scholar
• Kane C, O’Neil K, Conk M, Picha K. Inhalation delivery of protein therapeutics. Inflamm Allergy Drug Targets. 2013;12:81–87.
   PubMedGoogle Scholar
• Byron P, Patton J. Drug delivery via the respiratory tract. J Aerosol Med. 1994;7:49–75.
   PubMedGoogle Scholar
• Mortensen N, Hickey A. Targeting inhaled therapy beyond the lungs. Respiration. 2014;88:353–64.
   PubMed Web of Science ®Google Scholar
• Pera T, Penn R. Bronchoprotection and bronchorelaxation in asthma: new targets and new ways to target old ones. Pharmacol Ther. 2016;164:82–96.
   PubMed Web of Science ®Google Scholar
• Frohlich E, Salar-Behzadi S. Oral inhalation for the delivery of proteins and peptides to the lungs. Eur J Pharm Biopharm. 2021;163:198–211.
   PubMed Web of Science ®Google Scholar
• Secher T, Mayor A, Heuze-Vourc’h N. Inhalation of immunotherapeutics/prophylactics to fight respiratory tract infections. An appropriate drug at the right place. Front Immunol. 2019;10:2760.
   PubMed Web of Science ®Google Scholar
• Szleifer I. Protein adsorption on surfaces with grafted polymers: a theoretical approach. Biophys J. 1997;72:595–612.
   PubMed Web of Science ®Google Scholar
• Vazquez-Rey M, Lang D. Aggregates in monoclonal antibody manufacturing processes. Biotechnol Bioeng. 2011;108:1494–508.
   PubMed Web of Science ®Google Scholar
• Tiwari P, Vanover D, Lindsay K, Bawage S, Kirschman J, Bhosle S, Lifland A, Zurla A, Santangelo P. Engineered m-RNA-expressed antibodies prevent respiratory syncitial virus. Nature Commun. 2018;9:3999.
   PubMed Web of Science ®Google Scholar
• Stewart I, Richardson Z, Lai S, Hickey A. Nebulized aerosol characterization toward reinforcement of airway mucosal defense against pathogens. In: Dalby R, Byron P, Peart J, Suman J, MYoung P, Traini D, editors. Respiratory drug delivery. River Grove (IL): DHI Publishing; 2018. p. 509–12.
   Google Scholar
• Hertel S, Winter G, Friess W. Protein stability in pumonary drug delivery via nebulization. Adv Drug Del Rev. 2015;93:79–94.
   PubMed Web of Science ®Google Scholar
• Frokjaer S, Otzen D. Protein drug stability: a formulation challenge. Nature Rev Drug Disc. 2005;4:298–306.
   PubMed Web of Science ®Google Scholar
• Daugherty A, Mrsny R. Formulation and delivery issues for monoclonal antibody therapeutics. Adv Drug Del Rev. 2005;58:686–706.
   Web of Science ®Google Scholar
• Wang W, Singh S, Zeng D, King K, Nema S. Antibody, structure, instability, and formulation. J Pharm Sci. 2007;96:1–26.
   PubMed Web of Science ®Google Scholar
• Liang W, Pan H, Vllasaliu D, Lam J. Pulmonary delivery of biological drugs. Pharmaceutics. 2020;12:1025.
   PubMed Web of Science ®Google Scholar
• Desoubeaux G, Reichert J, Sleeman M, Reckamp K, Ryffel B, Adamczewski J, Sweeney T, Vanbever R, Diot P, Owen C, Page C, Lerondel S, Le Pape A, Heuze-Vourc'h N. Therapeutic monoclonal antibodies for respiratory diseases: current challenges and perspectives. March 31-April 2nd, 2016. Vol. 8. Tours (France): Mabs; 2016:999–1009.
   Google Scholar
• Cruz-Teran C, Tiruthani K, McSweeney M, Ma A, Pickles R, Lai S. Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy. Adv Drug Del Rev. 2021;169:100–17.
   PubMed Web of Science ®Google Scholar
• https://clinicaltrials.gov/ct2/show/NCT04631705.
   Google Scholar
• https://clinicaltrials.gov/ct2/show/NCT03473236.
   Google Scholar
• https://clinicaltrials.gov/ct2/show/NCT04341116.
   Google Scholar
• https://www.clinicaltrials.gov/ct2/show/NCT04518410.
   Google Scholar
• Rees V. Inhaled antibody treatment for COVID-19 shows success in preclinical trials – AR711. Eur Pharm Rev. 2020;News.
   Google Scholar
• [accessed 2021 May 04]. https://clinicaltrials.gov/ct2/show/NCT00138411.
   Google Scholar
• Morishita M, Peppas N. Is the oral route possible for peptide and protein drug delivery? Drug Discov Today. 2006;11:905–10.
   PubMed Web of Science ®Google Scholar
• Awwad S, Angkawinitwong U. Overview of antibody drug delivery. Pharmaceutics. 2018;10:83.
   Google Scholar
• Matucci A, Vultaggio A, Danesi R. The use of intravenous versus subcutaneous monoclonal antibodies in the treatment of severe asthma: a review. Respir Res. 2018;19:154.
   PubMed Web of Science ®Google Scholar
• Lu D, Hickey A. Pulmonary vaccine delivery. Expert Rev Vaccines. 2007;6:213–26.
   PubMed Web of Science ®Google Scholar
• Wang S, Thompson A, Hickey A, Staats H. Dry powder vaccines for mucosal administration: critical factors in manufacture and delivery. Curr Top Microbiol Immunol. 2012;354:121–56.
   PubMed Web of Science ®Google Scholar
• Hickey A. Controlled delivery of inhaled therapeutic agents. J Controlled Rel. 2014;190:182–88.
   PubMed Web of Science ®Google Scholar
• Hickey A. Emerging trends in inhaled drug delivery. Adv Drug Del Rev. 2020;157:63–70.
   PubMed Web of Science ®Google Scholar
• Niven R. Delivery of biotherapeutics by inhalation aerosol. Crit Rev Ther Drug Carrier Syst. 1995;12:151–231.
   PubMed Web of Science ®Google Scholar
• Laptos T, Omersel J. The importance of handling high-value biologicals: physico-chemical instability and immunogenicity of monoclonal antibodies. Exp Ther Med. 2018;15:3161–68.
   PubMed Web of Science ®Google Scholar
• Ameri M, Maa Y-F. Spray drying of biopharmaceuticals: stability and process considerations. Drying Technology. 2006;26:763–68.
   Google Scholar
• Basle YL, Chennell P, Tokhadze N, Astier A, Sautou V. Physico-chemical stability of monoclonal antibodies: a review. J Pharm Sci. 2020;109:169–90.
   PubMed Web of Science ®Google Scholar
• Ripple DC, Dimitrova MN. Protein particles: what we know and what we do not know. J Pharm Sci. 2012;101:3568–79.
   PubMed Web of Science ®Google Scholar
• Couston R, Skoda M, Uddin S, Cvd W. Adsorption behavior of human monoclonal antibody at hydrophobic and hydrophilic surfaces. Mabs. 2013. 126–39.
   Google Scholar
• Glover I, Basa L, Moore B, Laurence J, Sreedhara A. Metal ion interactions with mAbs: part 1. Mabs. 2015;7:901–11.
   PubMed Web of Science ®Google Scholar
• Chennamsetty N, Voynov V, Kayser V, Helk B, Trout B. Design of therapeutic proteins with enhanced stability. Proc Natl Acad Sci USA. 2009;106:11937–42.
   PubMed Web of Science ®Google Scholar
• Narang A, Krause M, Pizzarro S, Yee J. Biologic drug substance and drug product manufacture. In: Hickey A, Rocha S, editors. Pharmaceutical Inhalation Aerosol Technology. Boca Raton (FL): CRC Press; 2019. p. 206–32.
   Google Scholar
• Arosio P, Jaquet B, Wu H, Morbidelli M. On the role of salt type and concentration on the stability behavior of monoclonal antibody solution. Biophys Chem. 2012;168-169:19–27.
   PubMed Web of Science ®Google Scholar
• Karow A, Bahrenburg S, Garidel P. Buffer capacity of biologics–from buffer salts to buffering by antibodies. Biotechnol Prog. 2013;29:480–92.
   PubMed Web of Science ®Google Scholar
• Wang S, Wu G, Zhang X, Tian Z, Zhang N, Hu T, Dai W, Qian, F. Stabilizing two IgG1 monoclonal antibodies by surfactants: balance between aggregation prevention and structure perturbation. Eur J Pharm Biopharm. 2017;114:263–77.
   PubMed Web of Science ®Google Scholar
• Nicoud L, Cohrs N, Arosio P, Norrant E, Morbidelli M. Effect of polyol sugars on the stabilization of monoclonal antibodies. Biophys Chem. 2015;197:40–46.
   PubMed Web of Science ®Google Scholar
• Arakawa T, Timasheff S. Mechanism of polyethylene glycol interaction with proteins. Biochemistry. 1985;24:6756–62.
   PubMed Web of Science ®Google Scholar
• Faghihi H, Najafabadi A, Vatanara A. Optimization and characterization of spray-dried IgG formulations: a design of experiment approach. DARU J Pharm Sci. 2017;25:22.
   Web of Science ®Google Scholar
• Emami F, Vatanara A, Park E, Na D. Drying Technologies for the Stability and Bioavailability of Biopharmaceuticals. Pharmaceutics. 2018;10:131.
   PubMed Web of Science ®Google Scholar
• Hickey A, Ganderton D. Statistical experimental design. Pharmaceutical Process Engineering. New York (NY): Informa Healthcare; 2010. 197–201.
   Google Scholar
• Young A. Powder X-ray Diffraction and its application to biotherapeutic formulation development. American Pharm Rev. 2012;15:38371.
   Google Scholar
• Greenfield N. Using circular dichroism spectra to estimate protein secondary structure. Nat Protoc. 2006;1:2876–90.
   PubMed Web of Science ®Google Scholar
• Chakrabarti A. Separation of Monoclonal Antibodies by Analytical Size Exclusion Chromatography. In: Böldicke T, editors. IntechOpen. 2018. 73321.
   Google Scholar
• deJong L, Uges D, Frank J, Bischoff R. Receptor–ligand binding assays: technologies and applications. J Chromatography B. 2005;829:1–25.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Pan H, Chen X. Mass spectrometry for structural characterization of therapeutic antibodies. Mass Spec Rev. 2008;28:147–76.
   Web of Science ®Google Scholar
• Hnasko T, Hnasko R. The western blot. In: Hnasko R, editor. Elisa methods and protocols. New York (NY): Springer; 2015. p. 87–96.
   Google Scholar
• Taylor SC, Posch A. The design of a quantitative western blot experiment. Biomed Res Int. 2014;2014:361590.
   PubMed Web of Science ®Google Scholar
• Tokunaga Y, Takeuchi K. Role of NMR in high ordered structure characterization of monoclonal antibodies. Int J Mol Sci. 2021;22:46.
   Web of Science ®Google Scholar
• Bramham J, Podmore A, Davies S, Golovanov A. Comprehesive assessment of protein and excipient stability in biopharmaceutical formulations using 1H NMR spectroscopy. ACS Pharmacol Transl Sci. 2021;4:288–95.
   PubMedGoogle Scholar
• Sakuma C, Yomioka Y, Li C, Nakagawa M, Kurosawa Y, Arakawa T, Akuta T. Analysis of protein denaturation, aggregation and post-transcriptional modification by agarose native gel electrophoresis. Int J Biol Macromol. 2021;172:589–96.
   PubMed Web of Science ®Google Scholar
• Shaw M, Riederer B. Sample preparation for two-dimensional gel electrophoresis. Proteomics. 2003;3:1408–17.
   PubMed Web of Science ®Google Scholar
• USP-NF. General Chapter <5> Inhalation and nasal drug products - general information and product quality tests. Rockville (MD): United States Pharmacopeia; 2020.
   Google Scholar
• Fda(cder U. Metered dose inhaler (MDI) and dry powder inhaler (DPI) products - Quality Considerations. Silver Spring (MD): US Department of Health and Human Services; 2018.
   Google Scholar
• Cundell T. Mould contamination in pharmaceutical drug products and medical devices. Eur Pharm Rev. 2013;18:67–75.
   Google Scholar
• Blanchard J, Coleman J, Hayling CDA, Ghaderi R, Haeberlin B, Hart J, Jensen S, Malcomson R, Mittelman S, Nagao LM, Sekulic S, Snodgrass-Pilla C, Sundahl M, Thompson G, Wolff R. Foreign Particles Testing in Orally Inhaled and Nasal Drug Products. Pharm Res. 2004;21:2137–3147.
   PubMed Web of Science ®Google Scholar
• Bodier-Montagutelli E, Respaud R, Perret G, Baptista L, Duquenne P, Heuzé-Vourc’h N,Vecellio L. Protein stability during nebulization: mind the collection step! Eur J Pharm Biopharm. 2020;152:23–34.
   PubMed Web of Science ®Google Scholar
• Bodier-Montagutelli E, Mayor A, Vecellio L, Respaud R, Heuzé-Vourc’h N. Designing inhaled protein therapeutics for topical lung delivery: what are the next steps? Expert Opinion Drug Deliv. 2018;15:729–36.
   PubMed Web of Science ®Google Scholar
• Respaud R, Vecellio L, Diot P, Heuzé-Vourc’h N. Nabulization as a delivery method for Mabs in respiratory diseases. Expert Opinion Drug Deliv. 2015;12:1027–39.
   PubMed Web of Science ®Google Scholar
• Cipolla D, Gonda I. Method for collection of nebulized proteins. In: Cleland J, Langer R, editors. Formulation and Delivery of Proteins and Peptides. Washington (DC): Ameridcan Chemical Society; 1994. p. 343–52.
   Google Scholar
• USP-NF. General Chapter <601> Inhalation and nasal drug products: aerosols, sprays, and powders - performance quality tests. Rockville (MD): United States Pharmacopeia; 2020.
   Google Scholar
• Telko M, Hickey A. Dry powder inhaler formulation. Resp Care. 2005;50:1209–27.
   PubMedGoogle Scholar
• Edwards D, Hanes J, Caponetti G, Hrkach J, Ben-Jebrai A, Eskew M, Mintzes J, Deaver D, Lotan N, Langer R. Large porous particles for pulmonary drug delivery. Science. 1997;276:1868–72.
   PubMed Web of Science ®Google Scholar
• Maa Y-F, Nguyen P-A, Andya J, Dasovich N, Sweeney T, Shire S, Hsu CC. Effect of spray drying and subsequent processing conditions on residual moisture and physical/biochemical stability of protein inhalation powders. Pharm Res. 1998;15:768–75.
   PubMed Web of Science ®Google Scholar
• Maa Y-F, Nguyen P-A, Sweeney T, Shire S, Hsu C. Protein inhalation powders: spray drying vs spray-freeze drying. Pharm Res. 1999;16:249–54.
   PubMed Web of Science ®Google Scholar
• Vehring R. Pharmaceutical particle engineering via spray drying. Pharm Res. 2008;25:999–1022.
   PubMed Web of Science ®Google Scholar
• USP-NF. General Chapter <1601> Inhalation and nasal products - general information and product quality tests. Rockville (MD): United States Pharmacopeia; 2020.
   Google Scholar
• Hickey A. Quality and performance tests. In: Hickey A, editor. Inhaled pharmaceutical product development perspectives. New York (NY): Elsevier/RTI; 2018. p. 33–51.
   Google Scholar
• Apiou-Sbirlea G, Newman S, Fleming J, Siekmeier R, Ehrmann S, Scheuch G, Hochhaus G, Hickey A. Bioequivalence of inhaled drugs: fundamentals, challenges and perspectives. Ther Deliv. 2013;4:343–67.
   PubMedGoogle Scholar
• Hastedt J, Backman P, Clark A, Doub W, Hickey A, Hochhaus G, Kuehl PJ, Lehr C-M, Mauser P, McConville J, Niven R, Sakagami M, Weers JG. Scope and relevance of a pulmonary biopharmaceutical classification system AAPS/FDA/USP Workshop March 16-17th, 2015 in Baltimore, MD. AAPS Open. 2016;2:1.
   Google Scholar
• Hickey A. Back to the future: inhaled drug products. J Pharm Sci. 2013;102:1165–72.
   PubMed Web of Science ®Google Scholar
• Hickey A, Montgomery A. Aerosolized pentamidine for treatment and prophylaxis of Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome. In: Hickey A, editor. Pharmaceutical Inhalation Aerosol Technology. New York (NY): Marcel Dekker; 2004. p. 459–72.
   Google Scholar
• Pritchard J, Hollen D, Hatley R. Nebulizers. In: Hickey A, Rocha S, editors. Pharmaceutical Inhalation Aerosol Technology. Boca Raton (FL): CRC Press; 2019. p. 473–92.
   Google Scholar
• Schaefer A, Lai S. Innate and adaptive barrier properties of airway mucus. In: Hickey A, Mansour H, editors. Inhalation aerosols, physical and biological basis for therapy. New York (NY): CRC Press; 2019. p. 257–74.
   Google Scholar
• Blasco M, Ramos A, Malo C, Garcia-merino A. Acute pneumonitis and pericarditis related to alemtuzumab therapy in relapsing remitting multiple sclerosis. J Neurol. 2017;264:168–69.
   PubMed Web of Science ®Google Scholar
• Hansel T, Kropshofer H, Singer T, Mitchell J, George A. The safety and side effects of monoclonal antibodies. Nature Rev Drug Discovery. 2010;9:325–38.
   PubMed Web of Science ®Google Scholar
• Wolff R. Safety of inhaled protein for therapeutic use. J Aerosol Med. 1998;11:197–219.
   PubMedGoogle Scholar
• Guichard M-J, Leal T, Vanbever R. PEGylation an approach for improving the pulmonary delivery of biopharmaceuticals. Current Opinion in Colloid and Interface Sci. 2017;31:43–50.
   Web of Science ®Google Scholar
• Hickey A, Gonda I, Fildes F. Effect of hydrophobic coating on the behavior of a hygroscopic aerosol powder in an environment of controlled temperature and relative humidity. J Pharm Sci. 1990;79:1009–14.
   PubMed Web of Science ®Google Scholar
• Hickey A, Martonen T. Behavior of hygroscopic pharmaceutical aerosols and influence of hydrophobic additives. Pharm Res. 1993;10:1–7.
   PubMed Web of Science ®Google Scholar
• Garcia-Contreras L, Hickey A. Aerosol treatment of cystic fibrosis. Crit Rev Ther Drug Carrier Syst. 2003;20:317–56.
   PubMed Web of Science ®Google Scholar
• Ensign L, Hoen T, Maisel K, Cone R, Hanes J. Enhanced vaginal drug delivery though use of hypotonic formulations that induse fluid uptake. Biomaterials. 2013;34:6922–29.
   PubMed Web of Science ®Google Scholar
• Sahakijpijarn S, Smyth H, Miller D, Weers J. Post-inhalation cough with therapeutic aerosols: formulation considerations. Adv Drug Del Rev. 2020;166:127–41.
   Web of Science ®Google Scholar
• Ayehunie S, Wang -Y-Y, Landry T, Bogojevic S, Cone R. Hyperosmolal vaginal lubricant markedly reduce epithelial barrier properties in a three dimensional vaginal epithelium model. Toxicology Reports. 2018;5:134–40.
   PubMed Web of Science ®Google Scholar
• Guillaminault L, Azzopardi N, Arnoult C, Sobilo J, Hervé V, Montharu J, Guillon A, Andres C, Herault O, Le Pape A, Diot P, Lemarie E, Paintaud G, Gouilleux-Gruart V, Heuze-Vourc'h N. Fate of inhaled monoclonal antibodies after the deposition of aerosolized particles in the respiratory system. J Controlled Rel. 2014;196:344–54.
   PubMed Web of Science ®Google Scholar
• Guillon A, Pardessus J, Lhommet P, Parent C, Respaud R, Marchand D, Montharu J, De Monte M, Janiak P, Bioxel C, Audat H, Huille S, Guillot E, Heuze-Vourc'h N. Exploring the fate of inhaled monoclonal antibody in the lung parenchyma by microdialysis. Mabs. 2019;11:297–304.
   PubMed Web of Science ®Google Scholar
• Tang X, Pikal M. Design of freeze-drying processes for pharmaceuticals: practical advice. Pharm Res. 2004;21:191–200.
   PubMed Web of Science ®Google Scholar
• Hickey A. Fundamentals of dry powder inhaler technology. In: Merkus H, Meesters G, Oostra W, editors. Particles and nanoparticles in pharmaceutical products. New York (NY): Springer; 2020. p. 213–32.
   Google Scholar
• Hickey A. Complexity in pharmaceutical powders for inhalation: a perspective. KONA. 2018;35:3–13.
   Google Scholar
• Shetty N, Cipolla D, Park H, Zhou Q. Physical stability of dry powder inhaler formulations. Expert Opinion Drug Deliv. 2020;17:77–96.
   PubMed Web of Science ®Google Scholar
• Geller D, Heuerding S, Weers J. Development of an inhaled dry-powder formulation of tobramycin using PulmoSphereTM technology. J Aerosol Med Pulm Drug Deliv. 2011;24:175–82.
   PubMed Web of Science ®Google Scholar